Accelerate Diagnostics, Inc. (NASDAQ:AXDX) is scheduled to release its earnings data after the market closes on Thursday, November 2nd. Analysts expect Accelerate Diagnostics to post earnings of ($0.32) per share for the quarter.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01). Accelerate Diagnostics had a negative return on equity of 67.44% and a negative net margin of 5,062.48%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.40 million. On average, analysts expect Accelerate Diagnostics to post $-1.2 EPS for the current fiscal year and $-0.95 EPS for the next fiscal year.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) opened at 19.45 on Tuesday. Accelerate Diagnostics, Inc. has a 12-month low of $17.80 and a 12-month high of $30.45. The company’s market cap is $1.08 billion. The stock’s 50 day moving average is $21.47 and its 200 day moving average is $25.10.

A number of research firms have recently issued reports on AXDX. ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $34.00 price objective on shares of Accelerate Diagnostics in a research note on Wednesday, July 12th. Three investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. Accelerate Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $33.00.

In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 23,400 shares of the company’s stock in a transaction on Monday, August 14th. The stock was acquired at an average price of $21.35 per share, for a total transaction of $499,590.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jack W. Schuler acquired 8,200 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was acquired at an average price of $21.35 per share, with a total value of $175,070.00. The disclosure for this purchase can be found here. Insiders acquired a total of 655,622 shares of company stock valued at $13,251,092 in the last quarter. Corporate insiders own 50.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Accelerate Diagnostics, Inc. (AXDX) Set to Announce Earnings on Thursday, November 2nd” was reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/31/accelerate-diagnostics-inc-axdx-set-to-announce-earnings-on-tuesday.html.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.